NPAT collapsed 94.7% on flat revenue as margins and Australia weakened

EBITDA of NZ$12.6m delivered a 10.8% margin, which sits within Annolyse's historical range (mean 10.1%, range 8.1–12.7%), so the entire profit collapse is below the EBITDA line — depreciation, lease costs, and a higher effective tax rate (25.2% vs 29.2%) consumed what little operating profit remained.

The damage was concentrated in the dominant New Zealand segment, where revenue slipped to NZ$87.9m and segment result fell to NZ$4.1m from NZ$12.8m. Australia turned to a NZ$0.7m loss from a NZ$0.4m profit on slightly higher revenue. Operating cash flow halved to NZ$9.9m, capex tripled to NZ$7.3m (6.2% of revenue versus 1.6%), and pre-lease free cash flow fell to NZ$2.6m from NZ$17.7m.

• PBT growth (-94.4%) and NPAT growth (-94.7%) moved together, so the result is not a tax artefact. Management attributes the New Zealand profit hit to COVID-19 restrictions and ongoing global shipping disruption. This matters because the absolute earnings base — NZ$0.4m of NPAT on NZ$116.9m of revenue — leaves no operational buffer if either headwind persists into the second half.

• Working capital flattered cash. Debtor days came in at 43.7 days, an unprecedented low against the historical range of 50.6–56.4 days, and inventory days hit an unprecedented low of 34.1 versus a 40.3–44.3 range. The resulting NZ$4.3m working-capital release sits within the historical movement range, but the underlying receivables drop of NZ$6.5m is a one-off lever that cannot be repeated indefinitely.

• Capex tripled while earnings evaporated. Capex of NZ$7.3m versus NZ$1.9m prior (+277%) collided with halved operating cash flow, so free cash flow is now barely positive. Leverage at 3.79x net debt to EBITDA remains within Annolyse's historical range (2.9–6.0x), but ROE has collapsed from 18.2% to 1.0%.

Seasonality, however, is unfavourable: HY21 accounted for 88.5% of FY21 NPAT, so on the implied 2H21 NPAT contribution of just NZ$1.0m, MPG enters the seasonally weaker half from a starting point of NZ$0.4m. Annualising the current half gives implied FY22 revenue of NZ$233.7m, but matching FY21 NPAT of NZ$8.5m would require the second half alone to deliver more than 20x what HY22 delivered.

Management commentary that supply and COVID effects "are expected to continue" does not support that step-up. The FY21 release flagged an "intention to resume dividend payments alongside the FY22 interim results"; the supplied extraction shows no declared interim dividend, which is itself a signal.

Earnings durability is poor because EBITDA margin held inside its historical band but everything below it gave way, signalling that fixed-cost absorption is fine but pricing is not recovering input and freight cost inflation. Cash conversion of 78.6% reads well versus Annolyse's historical mean of 47.6%, but the underlying NZ$9.9m of OCF was assisted by the unprecedented receivables and inventory squeeze and still failed to fund the capex step-up.

• OCF NZ$9.9m, capex NZ$7.3m, pre-lease FCF NZ$2.6m
• FCF/NPAT of 627.2% reflects depressed NPAT, not strong cash generation
• Receivables down NZ$6.5m (-18.9%) provided a one-off working-capital lever

The combination — collapsed earnings, capex acceleration, and a working-capital release that has now largely been taken — means the cash buffer that softened this half is unlikely to be available next half.

This briefing cannot assess management's specific operational response to shipping disruption or its FY22 trading outlook beyond the COVID and freight commentary supplied in the release.